GLP-1 Medication Costs by State: 2026 Price Comparison

The cost of semaglutide and tirzepatide can vary dramatically depending on where you live. Brand-name Wegovy costs anywhere from $1,200 to $1,800 per month at retail pharmacies, while compounded alternatives range from $99 to $500 per month depending on the provider and state regulations. Understanding these variations helps you find the most affordable option.

Why GLP-1 Costs Vary by State

Regional Cost Overview

Northeast

Northeastern states generally have higher healthcare costs but also stronger insurance mandates. New York, Massachusetts, and Connecticut have been among the most progressive in requiring insurance coverage for anti-obesity medications. However, retail pharmacy prices for brand-name GLP-1 medications remain among the highest in the country. Local compounding pharmacy prices for semaglutide range from $200 to $450 per month.

Southeast

The Southeast presents a mixed picture. States like Florida and Texas have robust compounding pharmacy industries with competitive pricing, often $150 to $300 per month for compounded semaglutide. However, Medicaid coverage for GLP-1 medications is more limited, and insurance mandates are less common. Rural areas may have fewer local options.

Midwest

Midwestern states tend to have moderate healthcare costs. Local compounding options range from $175 to $350 per month. Insurance coverage varies significantly, with some states mandating coverage and others leaving it to employer discretion. Telehealth-based providers offer a consistent alternative to the local pricing variability.

West

Western states have generally progressive telehealth laws, making online GLP-1 providers accessible. California has particularly strong consumer protections and pharmacy regulations. Local compounding pharmacy prices range from $200 to $400 per month. Hawaii and Alaska face higher costs due to shipping and limited local pharmacy options.

The Nationwide Pricing Solution

Telehealth-based providers like Trimi eliminate geographic pricing variability entirely. Whether you live in Manhattan or rural Montana, you pay the same $99/mo for compounded semaglutide or $125/mo for compounded tirzepatide. This consistency is particularly valuable for patients in states with limited local compounding options or high pharmacy costs.

State Insurance Coverage Landscape

The insurance coverage picture for GLP-1 medications is evolving rapidly. Several states have passed or are considering legislation requiring insurers to cover FDA-approved anti-obesity medications. Even in states with mandates, coverage often applies only to brand-name medications, not compounded versions. For patients without insurance coverage, the compounded market offers the most accessible pricing.

Medicaid Coverage by State

Medicaid GLP-1 coverage varies dramatically. Some state Medicaid programs cover GLP-1 medications for both diabetes and obesity, while others restrict coverage to diabetes only or do not cover them at all. If you rely on Medicaid, check your state's current formulary. If your Medicaid does not cover GLP-1 medications, compounded alternatives at providers like Trimi may be more affordable than you expect.

Strategies for Every State

Regardless of where you live, several strategies apply universally. Compare local compounding pharmacy prices against telehealth providers. Check if your employer's insurance covers anti-obesity medications. Use HSA or FSA funds to pay with pre-tax dollars. Track expenses for potential tax deductions. And consider that the most affordable monthly cost often comes from telehealth providers with national compounding pharmacy partnerships.

The Bottom Line

Where you live should not determine whether you can afford GLP-1 treatment. While local pricing varies significantly, nationwide telehealth providers have democratized access to affordable compounded medications. Trimi's consistent pricing of $99/mo for semaglutide and $125/mo for tirzepatide is available in all 50 states, eliminating the geographic lottery of GLP-1 affordability.